Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Proto Labs IncPRLB · Entity 4553 | Chief Operations Officer | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Proto Labs Inc
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,683 |
Ending reported balance
After 2026-05-12 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 3,756 · Balance 30,942 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Row 2 · 2026-05-11 · Exercise / conversion · Acquired 3,677 · Balance 34,619 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. Row 3 · 2026-05-11 · Sale · Disposed 7,433 · Balance 27,186 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F2: Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2026-05-12 · Exercise / conversion · Acquired 1,928 · Balance 29,114 Row 5 · 2026-05-12 · Exercise / conversion · Acquired 1,557 · Balance 30,671 Row 6 · 2026-05-12 · Exercise / conversion · Acquired 4,042 · Balance 34,713 Row 7 · 2026-05-12 · Sale · Disposed 1,613 · Balance 33,100 F3: Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 8 · 2026-05-12 · Sale · Disposed 4,198 · Balance 28,902 F4: Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 9 · 2026-05-12 · Sale · Disposed 3,576 · Balance 25,326 F5: Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 10 · 2026-05-12 · Sale · Disposed 6,643 · Balance 18,683 F6: Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2033-02-14 | Direct | 3,856 |
Reported balance
After 2026-05-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-11 · Exercise / conversion · Disposed 3,756 · Balance 3,856 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.52 · Expires 2034-02-13 | Direct | 3,778 |
Reported balance
After 2026-05-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-11 · Exercise / conversion · Disposed 3,677 · Balance 3,778 F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025. F8: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2033-02-14 | Direct | 1,928 |
Reported balance
After 2026-05-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-12 · Exercise / conversion · Disposed 1,928 · Balance 1,928 F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.61 · Expires 2035-02-25 | Direct | 4,674 |
Reported balance
After 2026-05-12 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-12 · Exercise / conversion · Disposed 1,557 · Balance 4,674 F9: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.40 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-05-12 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-05-12 · Exercise / conversion · Disposed 4,042 · Balance 0 F10: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.
F2: Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested.
F8: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
F9: 25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
F10: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 21:04 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantPerformance Stock Units · Derivative | 1,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-003674 · rdgdoc.xml · derivative · entry 3 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894 Underlying: Common Stock · 1,894 shares Expires 2024-12-31 F4 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F4 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:04 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 4,042 | $0.00 Strike: $59.40 | $0.00 |
DisclosureSEC source: 0001437749-22-003674 · rdgdoc.xml · derivative · entry 2 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,042 Underlying: Common Stock · 4,042 shares Expires 2032-02-13 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:04 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 3,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-003674 · rdgdoc.xml · nonDerivative · entry 1 Kenison Michael R. · CIK 0001870293 · VP and GM of the America's 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,221 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. F2 · balance_after: Reports the total number of shares of Common Stock of the issuer held by the reporting person including 95 shares purchased on November 15, 2021 through the issuer's Employee Stock Purchase Plan program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.